¿Qué lugar tiene la medición de la proteína catiónica de los eosinófilos (ECP) en la valoración de la gravedad del asma?

Allergologia et Immunopathologia

Volumn 28, Issue 3, 2000, Pages 119-124

  Nieto, A ^a  

^a NONE

Author keywords

Asthma; Chronic inflammation disease; ECP; Eosinophil cationic protein; Inflammation

Indexed keywords

BIOLOGICAL MARKER; EOSINOPHIL GRANULE PROTEIN; PLASMA PROTEIN; RIBONUCLEASE;

ASTHMA; BLOOD; CHEMISTRY; CHILD; EOSINOPHIL; HUMAN; INFANT; INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; PROGNOSIS; REVIEW; SPUTUM;

ASTHMA; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHILD; CHILD, PRESCHOOL; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; HUMANS; INFANT; INFLAMMATION; PROGNOSIS; RIBONUCLEASES; SPUTUM;

EID: 0040522238     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Persson CGA. Centennial notions of asthma as an eosinophilic, desquamative, exudative, and steroid-sensitive disease. Lancet 1997;349:1021-4.
2. Sheffer AL, Bartal M, Bousquet J, Carrasco E, Chen Y-Z, Chuchalin AG et al. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. In: Health Nlo, editor; 1995. p. 1995.
3. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma an after bronquial provocation. Am Rev Respir Dis 1989;139:806-17.
4. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993;147:697-704.
5. Vignola AM, Chanez P, AM. C, Souques F, Lebel B, Enander I et al. Airway inflammation in mild intermitent and in persistent asthma. Am J Respir Crit Care Med 1998;157:403-9.
6. Hogg C, Bush A. Childhood asthma-all that wheezes is not inflammation. Clin Exp Allergy 1997;27:991-4.
7. Smith L, McFadden ER. Bronchial hyperreactivity revisited. Ann Allergy Asthma Immunol 1995;74:454-69.
8. Fish JE, Peters SP. Airway remodeling and persistent airway obstruction in asthma. J Allergy Clin Immunol 1999;104:509-16.
9. Mc Fadden ER. Asthma: morphologic-physiologic interactions. Am J Respir Crit Care Med 1994;150:S23-S26.
10. Marone G. Asthma: recent advances. Immunol Today 1998;19:5-9.
11. Venge P. Soluble markers of allergic inflammation. ACI News 1993;5:128-30.
12. Barnes PJ, Holgate ST, Laitinen LA, Pauwels R. Asthma mechanisms, determinants of severity and treatment: the role of nedocromil sodium. Report of a workshop held in Whistler, British Columbia, Canada, 18-19 May 1995. Clin Exper Allergy 1995;25:771-87.
13. Wardlaw AJ. Molecular basis for selective eosinophil traffiking in asthma: A multistep paradigm. J Allergy Clin Immunol 1999;104:917-26.
14. Venge P, Dahl R, Hällgren R, Olsson I. Cationic proteins of human eosinophils and their role in the inflammatory reaction. In: Mahmoud ADF, Austen KF, editors. The eosinophil in health and disease. Stokolm; 1993. p. 131-46.
15. Dahl R. Monitoring bronchial asthma in the blood. Allergy 1993;48:77-80.
16. Niimi A, Amitani R, Suzuki K, Tanaka E, Murayama T, Kuze F. Eosinophilic inflammation in cough variant asthma. Eur Respir J 1998;11:1064-69.
17. Niimi A, Amitani R, Suzuki K, Tanaka E, Murayama T, Kuze F. Serum eosinophilic cationic protein as a marker of eosinophilic inflammation in asthma. Clin Exper Allergy 1998:28:233-40.
18. Reijonen TM, Kosppi M, Kuikka L, Savolainen K, Kleemola M, Mononen I et al. Serum eosinphilic cationic protein as a predictor of wheezing after bronchiolitis. Pediatr Pulmonol 1997;23:397-403.
19. Reijonen TM, Korppi M, Kleemoila M, Savolainen K, Kuikka L, Mononen I et al. Nasopharyngeal eosinophil cationic pro-tein in bronchiolitis: relation to viral findings and subsequent wheezing. Pediatr Pulmonol 1997;24:35-41.
20. Koller DY, Wojnarowski C, Herkner KR, Weinländer G, Raderer M, Eichler I et al. High levels of eosinophilic cationic protein in wheezing infants predict the development of asthma. J Allergy Clin Immunol 1997;99:752-6.
21. Villa JR, Garcia G, Rueda S, Nogales A. Serum eosinophilic cationic protein may predict clinical course of wheezing in young children. Arch Dis Child 1997;78:448-52.
22. Venge P. Serum measurements of eosinophil cationic protein (ECP) in bronchial asthma. Clin Exp Allergy 1993;23:S3-S7.
23. Wever AM, Wever-Hess J, Hensgens HE, Hermans J. Serum eosinophil cationic protein (ECP) in chronic asthma. Relationship to spirometry, flow-volume curves, PC20, and exacerbations. Respir Med 1994;88:613-21.
24. Koller DY, Herouy Y, Götz M, Hagel E, Urbanek R, Eichler I. Clinical value of monitoring eosinophil activity in asthma. 73 1995(413-17).
25. Ädelroth E, Rosenhall L, Johansson S-A, Linden M, Venge P. Inflammatory cells and eosinophil activity in asthmatic investigated by bronchoalveolar lavage. Am Rev Respir Dis 1990;142:91-9.
26. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen allergic patiens. J Allergy Clin Immunol 1988;82:470-80.
27. Venge P, Dahl R, Petersen CGB. Eosinophil granule proteins in serum after allergen challenge of asthmatic patients and the effect of anti-asthmatic medication. Intern Arch Allergy Appl Immunol 1988;87:306-12.
28. Venge P, Dahl R. Are blood eosinophil number and activity for the development of the late asthmatic reaction after allergen challenge? Eur J Respir Dis 1989;2suppl 6:5439-4.
29. Dahl R, Venge P, Olsson I. Variations of blood eosinophils and eosinophil cationic protein during inhalation challenge test. Allergy 1978;33:211-5.
30. Hedlin C, Ahlstedt S, Hakanson L, Venge P. Levels in serum of eosinophilic cationic protein (ECP), eosinophil chemotactic activity (ECA), and tryptase before and during bronchial challenge in cat allergic children with asthma. Ped Allerg Immunol 1992;3:144-9.
31. Yoshikawa T, Shoji S, Fujii T, Kanazawa H, Kudoh S, Hirata K et al. Severity of exercise-induced bronchoconstriction is related to airway eosinophilic inflamation in patients with asthma. Eur Respir J 1998;12:879-84.
32. Boner AL, Peroni D, Sette L, Valletta EA, Piacentini G. Effects of allergen exposure-avoidance on inflammation in asthmatic children. Allergy 1993;48:119-24.
33. Boner AL, Peroni DG, Piacentini GL, Venge P. Antigen avoidance in a mountain environment .III. Influence on serum markers of eosinophil activation in children with allergic asthma. J Allergy Clin Immunol 1993.
34. Rak S, Björnson A, Hakansson L, Sörenson S, Venge P. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991;88:878-88.
35. Rak S. Effects of immunotherapy on the inflammation in pollen asthma. Allergy 1993;48:125-8.
36. Zimmerman B, Tsui F. Can the measurement of serum ECP be used to monitor treatment of childhood asthma with inhaled steroids? Allergy 1993;48:129-32.
37. Venge P, Henriksen J, Dahl R, Hakansson L. Exercise induced asthma and the generation of neutrophil chemotactic activity. J Allergy Clin Immunol 1990;85:498-504.
38. Zimmerman B. Clinical experience with measurement of ECP: uselfuness in the management of children with asthma. Clin Exp Allergy 1993;23:58-512.
39. Blanco DC, Castillo R, Ortega N, Álvarez M, Arteaga C, Barber D et al. Los ácaros como trofoalergenos. Alergol Inmunol Clin 1999;14:430-3.
40. Caffarelli C, Deriu FM, Terzi V, Perrone F, Angelis G, Atherton DJ. Gastrointestinal symptoms in patients with asthma. Arch Dis Child 2000;82:131-5.
41. Grossman J. One airway, one disease. Chest 1997;111:11S-16S.
42. Prieto L, Morales C. La rinitis alérgica y el asma como probables manifestaciones clínicas de un mismo proceso. Arch Bronconeumol 1998;34:277-80.
43. Togias A. Mechanisms of nose-lung interaction. Allergy 1999;54:S94-S105.
44. Wallaert B, Janin A, Lasalle P, Copin MC, Devisme L, Gosset P et al. Airway-like inflammation of minor salivary gland in bronchial asthma. Am J Respir Crit Care Med 1994;150:802-9.
45. Wallaert B, Desreumaux P, Copin MC, Tillie I, Benard A, Colombel JF et al. Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma. J Exp Med 1995;182:897-904.
46. Czech W, Krutmann J, Schopf E, Kapp A. Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. Br J Dermatol 1992;126:351-5.
47. Carlsen K-H, Halvorsen R, Pettersen M, Lødrup Carlsen KC. Inflammation markers and symptom activity in children with bronchial asthma. Influence of atopy and eczema. Pediatr Allergy Immunol 1997;8:112-20.
48. Winther L, Moseholm L, Reimert CM, Stahl Skov P, Kaergaard Poulsen L. Basophil histamine release, IgE, eosinophil counts, ECP, and EPX are related to the severity of symptoms in seasonal allergic rhinitis. Allergy 1999;54:436-45.
49. Lødrup Carlsen KC, Halvorsen R, Carlsen K-H. Serum inflammatory markers and effects of age and tobacco smoke esposure in young non-asthmatic children. Acta Paediatr 1998;87:559-64.
50. Kurtzhals JA, Reimert CM, Tette E, Dunyo SK, Koram KA, Akanmori BD et al. Increased eosinophil activity in acute Plasmodium falciparum infection-association with cerebral malaria. Clin Exp Immunol 1998;112:303-7.
51. Vanto T, Koskinen P. Serum eosinophil cationic protein in the evaluation of asthma severity in children. Allergy 1998;53:415-9.
52. Vilá-Indurain B, Muñoz-López F, Martín-Mateos MA. Evaluation of blood eosinophilia and the eosiniphil cationic protein (ECP) in the serum of asthmatic children with varying degree of severity. Allergol Immunopathol 1999;27:304-8.
53. Wojnarowski C, Roithner B, Koller DY, Halmerbauer G, Gartner C, Tauber E et al. Lack of relationship between eosinophil cationic protein and eosinophil protein X in nasal lavage and urine and the severity of childhood asthma in a 6-month follow-up study. Clin Exper Allergy 1999;29:926-32.
54. Sigurs N, Bjarnason R, Sigurbergsson F. Eosinophilic cationic protein in nasal sacretion and in serum and myeloperoxidase in serum in respiratory syncytial virus bronchiolitis: relation to asthma and atopy. Acta Paediatr 1994;83:1151-5.
55. Motojima S, Akutsu I, Fukuda T, Makino S, Takatsu K. Clinical significance of measuring levels of sputum and serum ECP and serum IL-5 in bronchial asthma. Allergy 1993;48:98-106.
56. Fahy JV, Woo Kim K, Liu J, Boushey HA. Prominent neutrophilic inflamation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995;95:843-52.
57. Jatakanon A, Uasuf C, Maziak W, Lim S, Fan Chung K, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care med 1999;160:1532-39.
58. Álvarez Puebla MJ, García Figueroa BE, Olaguibel Rivera JM. Analysis of induced sputum: a new approach to the study of airway inflammation in asthma. Invest Allergol Clin Immunol 1999;9:73-81.
59. Grebski E, Wu J, Wüthrich B, Medici TC. Does eosinophil cationic protein in sputum and blood reflect bronchial inflammation and obstruction in allergic asthmatics? Invest Allergol Clin Immunol 1999;9:82-8.
60. Ennis M, Turner G, Schock BC, Stevenson EC, Brown V, Fitch PS et al. Inflammatory mediators in bronchoalveolar lavage samples from children with and without asthma. Clin Exper Allergy 1999;29:362-16.
61. Gutiérrez V, Prieto L, Torres V, Trenor R, Pérez C, Bertó JM et al. Relationship between induced sputum cell counts and fluid-phase eosinophilic cationic protein and clinical or physiologic profiles in mild asthma. Ann Allergy Asthma Immunol 1999;82:559-65.